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A Reply to Comment on the Use of Vignettes and the EQ-5D to Value
Disease-Specific Health StatesTo the Editor – In this letter, we would like to address Kularatna et
al.’s concerns about our recent study “Estimation and Comparison of
EQ-5D Health States’ Utility Weights for Pneumococcal and Human
Papillomavirus Diseases in Argentina, Chile, and the United King-
dom” published in Value in Health. First, the authors of the letter ex-
press concerns about the use of vignettes. The approach we used is
neither novel nor unusual (some recent examples can be seen in
Janssen et al. [1] or Xie et al. [2]). Each vignette was designed to pres-
nt a disease as close to clinical reality as possible. Typical clinical
ases were depicted, and they were not oriented to map the EuroQol
ve-dimensional (EQ-5D) questionnaire (in fact, the variability we
ound in the scores for each condition as well as in the descriptive
tates shows this). Vignettes were indeed developed, as Kularatna et
l. suggest, by clinicians who have access on an everyday basis to
atients suffering from the studied conditions. Furthermore, the vi-
nettes were first piloted with members of the general population.
ecause of space constraints, some of these details were not de-
cribed in the article. We were confident though that interested read-
rs would contact us to get more information about this process.
Then the authors of the letter make reference to the translation
nd linguistic validation of the vignettes, taking for granted that the
ignettes were used in the United Kingdom, Chile, and Argentina.
nfortunately, this is a misunderstanding because, as is stated in the
tudy article, the vignettes were administered only in Argentina:
. . .12 health state vignettes (. . .) were designed, pilot-tested, and
dministered to a convenience sample of subjects in Argentina.” We
id it in only one country because the objective was to compare
Q-5D questionnaire health states’ preference values “using the
ame health states’ descriptive mix in the three countries” as is also
escribed in the beginning of the article. Furthermore, this is empha-
ized in the discussion because it is a central aspect of our study,
hich shows that “utility coefficients for each condition differed sig-
ificantly between the three analyzed countries even considering
hat the same health states’ mix was valued in all three countries.” If
his issue is not taken into consideration, the interpretation of the
hole study will be flawed. Needless to say, translation and linguistic
alidation were not explained simply because they were not needed.
Regarding Kularatna et al.’s suggestions about alternative meth-
ds, preference elicitation methods were never the main objective of
his study. Social preference values were already available, and so we
ere not interested in measuring them. On the other hand, obtaining
sample of patients for all health states in the three participant
ountries would have been ideal. If we collected data from patients in
he three countries though, we would have missed the opportunity
o compare EQ-5D questionnaire utility weights exclusively because
n that case both the five-digit EQ-5D questionnaire numbers and the
tility weights would have varied from country to country. Even if we
id it in only one country, this approach would have required pri-
ary data collection from patients in each of the 12 disease states,
nd recruiting sufficient number of subjects for each state of each of
he diseases was clearly out of our possibilities and plans.Finally, theauthorsofthecommentstronglyadvisenottorepeatour
approach but to use “sensible and scientifically valid methods” instead.
Many still assume that utility values used in economic evaluations are
transferable from place to place and use weights from other settings for
quality-adjusted life-year calculations, but it has been consistently
shown that there are systematic differences in social values among dif-
ferent countries-regions [3–9]. Therefore, we cannot emphasize enough
the relevance of advancing in the field, even with low-resource–inten-
sive approaches as the one we took. Because of the scarce research in
this area in Latin America and the high contribution of the reported
conditionstotheregionalburdenofdisease,westill thinkthatourstudy
has made a relevant regional contribution.
Thiswasasmallstudy,as isacknowledgedfromtheverybeginning,
“[a]lthoughthisstudywasasubstudyofa largerproject. . .”Thefact that
a study is small, however, is not related to its quality or the validity of its
results. Health states could indeed be described in a different way, but
this was not relevant in this practical exercise because what was tested
was whether the country valuations were significantly different using
the same set of health states. The fact that they are significantly differ-
ent addresses the importance of using local and not foreign weights in
context-specific analyses, and to show this with a realistic scenario was
the rationale of the study.
We understand Kularatna et al.’s concerns given the incomplete
flawed interpretation of the study. To indicate, however, that a study
lacks scientific validity is a rather serious matter and should be
soundly justified after a deep understanding of the objectives and
methods used in the study being criticized. Contact details are in-
cluded in every published article. Critics should evacuate all their
doubts through this channel before making such strong and general
remarks. Criticism in science is absolutely vital, but it should be as
sensible and scientifically valid as the work that is being criticized.
Julieta Galante, MD, MSc(c)
Economic Evaluations and HTA Department,
Institute for Clinical Effectiveness and Health Policy,
Buenos Aires, Argentina
Federico Augustovski, MD, MSc, PhD
Economic Evaluations and HTA Department,
Institute for Clinical Effectiveness and Health Policy,
Family and Community Medicine Division Hospital,
University of Buenos Aires,
Buenos Aires, Argentina
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1170–7.Comment on the Use of Vignettes and the EQ-5D to Value Disease-
Specific Health StatesTo the Editor – We are concerned about the techniques used in an
ttempt to elicit utility weights reported in the recent article by Gal-
nte et al. titled “Estimation and comparison of EQ-5D health states’
tility weights for pneumococcal and human papillomavirus dsease
n Argentina, Chile, and the United Kingdom” in the July/August
5, Suppl. 1) 2011 issue of Value in Health titled “3rd Special Issue:
Pharmacoeconomics and Outcomes Research in Asia” [1]. That study
aimed to estimate and compare the utility weights for health states
associated with pneumococcal and human papilloma virus for Ar-
gentina, Chile, and the United Kingdom.
The investigators developed eight vignettes for pneumococcal
health states and four vignettes for human papillomavirus states.
After the vignettes were described to convenience samples, subjects
completed the EuroQol five-dimensional (EQ-5D) questionnaire for
each state described. Their responses were collated as five-digit
numbers given for each EQ-5D questionnaire health state and paired
with their available corresponding utility weights in each country.
The major shortcoming with this approach is that the respond-
ers “rate” the health state description on the EQ-5D questionnaire.
If the health state was described by using the domains of mobility,
personal care, usual activities, pain, and anxiety/depression (i.e.,
the EQ-5D questionnaire domains), then the respondents merely
need to map the description to the EQ-5D questionnaire levels.
The health states that are well described would result in all re-
spondents scoring identical levels for each domain. For example, a
health state could be described as “no problems walking around,
some problems with washing or dressing, unable to perform usual
activities, moderate pain or distress, and extreme anxiety” and all
respondents would score this as 12323 on the EQ-5D question-
naire. For health state descriptions that match the domains of an
instrument (including those developed from an instrument), there
is no need to have respondents score the description. If the health
state descriptions do not include the domains used in the EQ-5D
questionnaire, however, then the respondents will struggle map-
ping the descriptions to the instrument; in this circumstance, the
instrument is not appropriate to use for the health state being
described because it lacks the necessary constructs for validity.
Unfortunately, Galante et al. [1] do not describe the development
of the vignettes or the translation or the linguistic validation of the
vignettes, given that the study was carried out in three countries.
Rather than undertaking a poorly designed and flawed experi-
ment, there were at least two alternative methods open to the au-
thors [2]. One approach is scenario based using vignettes developed
with patients and clinical experts. The vignettes, in turn, can be val-the standard gamble or time trade-off where the value obtained for
each vignette may differ with the desirability or the preference of
each subject toward the given scenario [3]. The second more practical
method available to the authors would have been, because all the
three countries had already valued EQ-5D questionnaire utility
weights, to obtain a sample of “patients” with different degrees of
disease severity of pneumococcal and human papillomavirus in each
country and to administer the EQ-5D questionnaire to the patients to
describe the health state they were experiencing. Then the appropri-
ate utility scoring algorithm for the respective country could be ap-
plied [4].
We cannot emphasize enough the need to use sensible and
scientifically valid methods rather than repeating approaches
such as those described by Galante et al.
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